| Systemic onset juvenile chronic arthritis

Ilaris vs Actemra

Side-by-side clinical, coverage, and cost comparison for systemic onset juvenile chronic arthritis.

Deep comparison between: Ilaris vs Actemra with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsActemra has a higher rate of injection site reactions vs Ilaris based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Actemra but not Ilaris, including UnitedHealthcare

Category

Ilaris

Actemra

At A Glance

RouteSC injection

FrequencyEvery 4-8 weeks

ClassIL-1beta antagonist

RouteIV infusion or SC injection

FrequencyEvery 4 weeks (IV) or Every week to Every other week (SC)

ClassIL-6 receptor antagonist

Indications

Familial Cold Autoinflammatory Syndrome 1
Muckle-Wells Syndrome
Cryopyrin-Associated Periodic Syndromes
TNF receptor-associated periodic fever syndrome (TRAPS)
Hyperimmunoglobulinemia D
Familial Mediterranean Fever
Adult-Onset Still Disease
Systemic onset juvenile chronic arthritis
Gout

Rheumatoid Arthritis
Giant Cell Arteritis
Lung disease with systemic sclerosis
Juvenile polyarthritis
Systemic onset juvenile chronic arthritis
Cytokine Release Syndrome
COVID-19 Virus Disease

Dosing

Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome 1, Muckle-Wells Syndrome For patients >40 kg: 150 mg SC every 8 weeks; for patients >=15 kg and <=40 kg: 2 mg/kg SC every 8 weeks (inadequate response in pediatric patients: 3 mg/kg every 8 weeks).

TNF receptor-associated periodic fever syndrome (TRAPS), Hyperimmunoglobulinemia D, Familial Mediterranean Fever For patients >40 kg: 150 mg SC every 4 weeks (may increase to 300 mg every 4 weeks if response is inadequate); for patients <=40 kg: 2 mg/kg SC every 4 weeks (may increase to 4 mg/kg every 4 weeks if response is inadequate).

Adult-Onset Still Disease, Systemic onset juvenile chronic arthritis For patients >=7.5 kg: 4 mg/kg (maximum 300 mg) SC every 4 weeks.

Gout 150 mg SC as a single dose; if re-treatment is required, an interval of at least 12 weeks must elapse before a new dose.

Rheumatoid Arthritis IV: 4 mg/kg every 4 weeks, increase to 8 mg/kg every 4 weeks based on response; SC: 162 mg every other week (for <100 kg) or every week (for >=100 kg), increase to every week based on response.

Giant Cell Arteritis IV: 6 mg/kg every 4 weeks with tapering glucocorticoids; SC: 162 mg every week with tapering glucocorticoids (may use every other week based on clinical considerations).

Systemic Sclerosis-Associated Interstitial Lung Disease SC: 162 mg every week.

Polyarticular Juvenile Idiopathic Arthritis IV: 10 mg/kg every 4 weeks (<30 kg) or 8 mg/kg every 4 weeks (>=30 kg); SC: 162 mg every 3 weeks (<30 kg) or every 2 weeks (>=30 kg).

Systemic Juvenile Idiopathic Arthritis IV: 12 mg/kg every 2 weeks (<30 kg) or 8 mg/kg every 2 weeks (>=30 kg); SC: 162 mg every 2 weeks (<30 kg) or every week (>=30 kg).

Cytokine Release Syndrome IV: 12 mg/kg (<30 kg) or 8 mg/kg (>=30 kg) as single dose, alone or with corticosteroids; up to 3 additional doses at least 8 hours apart if no improvement.

COVID-19 IV: 12 mg/kg (<30 kg) or 8 mg/kg (>=30 kg) as single 60-minute infusion; one additional dose at least 8 hours later if clinical signs worsen or do not improve.

Contraindications

Confirmed hypersensitivity to canakinumab or to any of the excipients

Known hypersensitivity to tocilizumab

Drug Interactions

1223View drug interactions

856View drug interactions

Adverse Reactions

Most common (>=10%) nasopharyngitis, injection-site reactions, infections, diarrhea, influenza, rhinitis, nausea, headache, abdominal pain, musculoskeletal pain, vertigo, weight increased

Serious serious infections (pneumonia, varicella, sepsis, intra-abdominal abscess, conjunctivitis, pharyngotonsillitis), macrophage activation syndrome, neutropenia

Postmarketing Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

Most common (>=5%) Upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, injection site reactions (SC only).

Serious Serious infections (pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, bacterial arthritis), gastrointestinal perforations, hypersensitivity reactions including anaphylaxis.

Postmarketing Fatal anaphylaxis, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), pancreatitis, drug-induced liver injury, hepatitis, hepatic failure, jaundice, hypofibrinogenemia.

Pharmacology

IL-1beta antagonist; canakinumab is a human monoclonal IgG1/kappa antibody that selectively binds human IL-1beta and neutralizes its activity by blocking its interaction with IL-1 receptors, without binding IL-1alpha or IL-1 receptor antagonist, thereby reducing IL-1beta-driven inflammation in autoinflammatory and crystal-induced diseases.

Tocilizumab is a humanized IgG1 kappa monoclonal antibody that binds to soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling involved in inflammatory and immune processes.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Ilaris